Launch of a cardiac-enriched lncRNA panel by Firalis and Celemics

Firalis resized.png

Firalis S.A. and Celemics, Inc. announce an agreement for the commercialization of a unique proprietary long non-coding RNA (lncRNA) panel, FiMICS®.  The precise quantification of 3233 cardiac-enriched lncRNAs in peripheral blood samples would better characterize patients with diverse cardiac disorders and toxicities.

Cardiolinc TM 1 small.png

Firalis S.A. (“Firalis”), a Huningue based developer and provider of biomarker diagnostic products and bioanalytical services for research and diagnostic use and Celemics, Inc. (“Celemics”), a Seoul based provider of targeted enrichment of genomic technology for Next-Generation Sequencing (NGS) application, instruments and reagents for molecular biology, today announced a development and supply agreement (“Agreement”) that will enable Firalis to commercialize a Next-Generation Sequencing-based product “FiMICS" to quantify cardiac-enriched long non-coding RNAs (lncRNAs).

Identification of increasing numbers of lncRNAs, their involvement in many important pathophysiological pathways, and in particular their tissue specific expression, make them a very interesting source for identification of new therapeutic and diagnostic targets. In collaboration with several research institutes of excellence, including Luxembourg Institute of Health (LIH) and the “Centre Hospitalier Universitaire Vaudois, (CHUV)” in Lausanne, Firalis recently identified more than 3233 cardiac-enriched lncRNAs. Out of them 1066 lncRNAs have never been previously described.

Thanks to the top ranked Eurostars-South Korean project HeartLINC, coordinated by Firalis, and the joint efforts from Cardiolinc™ network members (, the FiMICS panel has been developed in collaboration with Celemics. "We are very happy to help Firalis for the development of this innovative tool that should bring a fresh wind in the medical sector and open new possibilities in R&D pipelines of pharmaceutical and diagnostic companies", said Dr. Hyoki Kim, the CEO of Celemics.

“We are very impressed by the analytical performance of the FiMICS panel that easily quantifies thousands of cardiac-enriched lncRNAs in peripheral whole blood samples. The panel will be a great source of new therapeutic and diagnostic discoveries in the coming years for pathologies in which heart is involved, said Prof. Hüseyin Firat, CEO of Firalis.

The availability of the lncRNA panel opens a great avenue for new therapeutics and precision medicine tools for diverse primary and secondary cardiac diseases, cardiac toxicities, and for drug development. FiMICS will foster investigations in multifactorial cardiac disorders such as heart failure for patient’s benefit", said Dr Yvan Devaux, who leads the Cardiovascular Research Unit at LIH and chairs the Cardiolinc™ network.

The Agreement with Celemics is a next step in the parties’ relationship for the development of new RUO and IVD tools, for the quantification of lncRNAs, and to improve the management of cardiac diseases for a better patient care.



Firalis is a biotechnology company with a mission to improve disease outcome, therapeutic decisions and generate savings in healthcare through biomarker discovery, development and regulatory qualification that ultimately leads to biomarker-based diagnostics. Firalis develops and markets RUO (Research-use-only) and IVD (In-vitro-diagnostic) kits in the field of cardiovascular with particular interest in heart failure. Using cutting-edge technology platforms in a very high-quality environment (ISO 9001, ISO 13845, ISO 17025 and NF S 96-900), Firalis provides a comprehensive range of biomarker services from research to clinical applications in key therapeutic areas.

To get further information on Firalis Biomarker Services and its capabilities to successfully level up customer’s projects, please contact


Florian Still, Head Business Development

Hüseyin Firat, Chief Executive Officer


About Celemics, Inc.

Celemics is a biotech company developing and supplying key enabling solutions in the field of genomics, antibody discovery and synthetic biology. As a manufacturer of target enrichment kits for NGS applications, Celemics secured itself in the global market as a pioneering of target enrichment methodology for genetic testing. Celemics offers customer flexible and customizable target enrichment kits in IVD and RUO sector with remarkable synthetic probe rebalancing technology under stringent quality management system (ISO 9001, ISO 13485, GMP). Founded 2010, Celemics has been focused in the last several years on providing target enrichment panels in Europe and Asia for various applications including oncology, inherited disease and genetic marker discovery.

To get further information on Celemics solutions, please contact


Celemics, Inc, Headquarter

Hyoki Kim, co-CEO

Yong Hoon Lee, co-CEO